June 13, 2014 — GE Healthcare introduced the Discovery NM/CT 670 Pro at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2014). Quantitative accuracy in nuclear medicine is enabled by Q.Metrix and Q.AC, GE Healthcare's newest software innovations in nuclear medicine.
The new Discovery NM/CT 670 Pro integrates the GE Optima CT 540 to maintain its cutting edge CT performance. It combines a 50-slice equivalent CT speed for extended fast coverage of time-critical scans with advanced CT applications, dose management tools such as OptiDose, DoseWatch and ASiR and a streamlined workflow for the most challenging standalone CT procedures.
Quantitative results have been an important part of nuclear medicine imaging for some time as a relative, qualitative assessment. Q.Suite for SPECT/CT represents the next step in GE Healthcare's vision to enable personalized, absolute quantitative SPECT/CT imaging. The two analysis and reporting applications in Q.Suite simplify organ definition and activity calculations to help raise report quality, while improving processing workflow and productivity.
Q.Metrix, a user-friendly application for measuring and reporting standard uptake values in the organ or lesion of interest, enables personalized, quantitative SPECT SUV results with multi-dimensional organ and lesion characterization.
Q.AC is an image reconstruction algorithm for improved accuracy of SPECT attenuation correction that enables quantitative SPECT measurements even at very low dose.
Dosimetry Toolkit, an advanced clinical application that has proven the potential of quantitative SPECT/CT, provides convenient tools for organ segmentation, registration, and activity calculations for Radio-Isotope Therapy planning. With new quantitative tools that generate accurate and more consistent measurements, clinicians can plan treatment therapy quicker and easier than ever before.
For more information: www.genewsroom.com
July 30, 2024 
